Hanna Gaggin (@hannagaggin) 's Twitter Profile
Hanna Gaggin

@hannagaggin

cardiologist, scientist, mom of 3 @MassGeneral @HarvardMed via @uva @EVMSedu @uvahealthnews @HarvardChanSPH @PittCardiology Personal views not of my employer

ID: 1028453803

linkhttps://www.massgeneral.org/doctors/doctor.aspx?id=19072# calendar_today22-12-2012 12:50:01

2,2K Tweet

1,1K Takipçi

1,1K Takip Edilen

Anu Lala-Trindade (@dranulala) 's Twitter Profile Photo

🚨 Dr Yololanda Colson, MD PhD Prof of thoracic surgery at MGH is the 🥇 1st PRESIDENT of #AATS !!!! 🙌🏽To breaking barriers down, continued progress & ⬆️representation! 🏆Congrats to our #CTSurgery colleagues & community 🫀🫶🏽 #SheLooksLikeASurgeon #AATS2022 #CTSN

🚨 Dr Yololanda Colson, MD PhD Prof of thoracic surgery at MGH is the 🥇 1st PRESIDENT of #AATS !!!!

🙌🏽To breaking barriers down, continued progress & ⬆️representation! 🏆Congrats to our #CTSurgery colleagues & community 🫀🫶🏽 #SheLooksLikeASurgeon #AATS2022 #CTSN
Gregg Fonarow MD (@gcfmd) 's Twitter Profile Photo

The very best way to “treat” outpatient worsening chronic heart failure is to…… Prevent it in the first place WHF dramatically less likely to occur if ARNI+BB+MRA+SGLT2i are started from day 1, then optimized HFSA

The very best way to “treat” outpatient worsening chronic heart failure is to……

Prevent it in the first place

WHF dramatically less likely to occur if ARNI+BB+MRA+SGLT2i are started from day 1, then optimized

<a href="/HFSA/">HFSA</a>
Peder L. Myhre MD, PhD (@pmyhre) 's Twitter Profile Photo

HF superstar Muthu Vaduganathan presented a very interesting analysis of combination therapy with MRA+ARNI+SGLT2i in HFmrEF and HFpEF at #HeartFailure2022 🥊Substantial benefits up to EF 60-65% Muthu Vaduganathan’s second SimPub in Circulation this meeting!!

HF superstar <a href="/mvaduganathan/">Muthu Vaduganathan</a> presented a very interesting analysis of combination therapy with MRA+ARNI+SGLT2i in HFmrEF and HFpEF at #HeartFailure2022 

🥊Substantial benefits up to EF 60-65%

<a href="/mvaduganathan/">Muthu Vaduganathan</a>’s second SimPub in <a href="/CircAHA/">Circulation</a> this meeting!!
Anthony Rosenzweig, MD (@rosenzweig_a) 's Twitter Profile Photo

Just out in @jaccjournals jacc.org/doi/10.1016/j.… our COVID proteomics study led by Jason Roh identifying actionable pathways in patients with cardiac involvement. Appreciate editorial by Drs. George Vasquez-Rios, MD MSCR, FASN and Girish Nadkarni jacc.org/doi/10.1016/j.…

Just out in  @jaccjournals jacc.org/doi/10.1016/j.… our COVID proteomics study led by Jason Roh identifying actionable pathways in patients with cardiac involvement.  Appreciate editorial by Drs. <a href="/GeorgeVasquezR2/">George Vasquez-Rios, MD MSCR, FASN</a> and Girish Nadkarni jacc.org/doi/10.1016/j.…
Yevgeniy Brailovsky DO MSc FACC (@yevgeniybr) 's Twitter Profile Photo

Great variability of parental benefits and policies among cardiovascular training programs can have negative impact on work-life balance. JACC Journals Incredible effort led by Estefania Oliveros MD🫀 Dr Roxana Mehran Ki Park Doreen DeFaria Yeh, MD Nosheen Reza, MD, MS @ErikaJSqueri jacc.org/doi/10.1016/j.…

Great variability of parental benefits and policies among cardiovascular training programs can have negative impact on work-life balance. <a href="/JACCJournals/">JACC Journals</a> Incredible effort led by <a href="/EstefaniaOS/">Estefania Oliveros MD🫀</a> <a href="/Drroxmehran/">Dr Roxana Mehran</a> <a href="/cardioPCImom/">Ki Park</a> <a href="/ddefariayeh/">Doreen DeFaria Yeh, MD</a> <a href="/noshreza/">Nosheen Reza, MD, MS</a> @ErikaJSqueri jacc.org/doi/10.1016/j.…
MGH Cardiology Fellows (@mghcvfellows) 's Twitter Profile Photo

We could not be more excited to welcome Dr Roxana Mehran for the 11th Annual Peter M. Yurchak Lecture. A true #WIC legend and inspiration. It’s going to be a great day! Mass General Heart #womensCVD #inclusionincardiology #CardioTwitter

Jason H. Wasfy, M.D. (@jasonwasfy) 's Twitter Profile Photo

Dr Roxana Mehran⁩ at Peter Yurchak ⁦Mass General Heart⁩ lecture - underrepresentation of women in trials is a barrier to understanding heterogeneous treatment effects and developing sex-specific treatment strategies ⁦Harvard Medical School⁩ ⁦MassGeneral News

⁦<a href="/Drroxmehran/">Dr Roxana Mehran</a>⁩ at Peter Yurchak ⁦<a href="/MGHHeartHealth/">Mass General Heart</a>⁩ lecture - underrepresentation of women in trials is a barrier to understanding heterogeneous treatment effects and developing sex-specific treatment strategies ⁦<a href="/harvardmed/">Harvard Medical School</a>⁩ ⁦<a href="/MassGeneralNews/">MassGeneral News</a>⁩
Muthu Vaduganathan (@mvaduganathan) 's Twitter Profile Photo

Clusters/phenotypes/phenomes/phenomaps/comorbidities are all theoretically appealing to classify HF yet need to rise to the bar that #LVEF has set: 1) key inclusion criteria in RCTs 2) powerful risk stratification of outcomes 3) strongest predictor of response to many #GDMT

Clusters/phenotypes/phenomes/phenomaps/comorbidities

are all theoretically appealing to classify HF

yet need to rise to the bar that #LVEF has set:

1) key inclusion criteria in RCTs
2) powerful risk stratification of outcomes
3) strongest predictor of response to many #GDMT
Sama Elrahi, MD (@s_elrahi) 's Twitter Profile Photo

I got this email 20 min ago & can't stop crying. My dad, a poor Lebanese immigrant, was never able to go to college & had to take care of his fam of 12 after his dad passed & worked so hard to make sure others could go to school. This degree & these awards are for you too, Baba.

I got this email 20 min ago &amp; can't stop crying. My dad, a poor Lebanese immigrant, was never able to go to college &amp; had to take care of his fam of 12 after his dad passed &amp; worked so hard to make sure others could go to school. This degree &amp; these awards are for you too, Baba.
Hanna Gaggin (@hannagaggin) 's Twitter Profile Photo

Congratulations @NanditaScott!!! You have led us through the pandemic with poise, inspiration and support! I am so proud to have you as a role model!

Nikhil Narang, MD (@nikhil15) 's Twitter Profile Photo

What are the implications of encountering a reduced EF (<40%) on initial presentation in patients with Cardiac Amyloidosis? What factors are associated with this? Outstanding new work from Trejeeve (Tre) Martyn W. H. Wilson Tang, MD in JACC Journals #JACCHF 📎 jacc.org/doi/10.1016/j.…

What are the implications of encountering a reduced EF (&lt;40%) on initial presentation in patients with Cardiac Amyloidosis? What factors are associated with this? Outstanding new work from <a href="/tremartyn/">Trejeeve (Tre) Martyn</a> <a href="/WilsonTangMD/">W. H. Wilson Tang, MD</a> in <a href="/JACCJournals/">JACC Journals</a> #JACCHF 

📎 jacc.org/doi/10.1016/j.…
Alfonso Valle (@vallealfonso) 's Twitter Profile Photo

Effects of ARNI on Major Coronary Events in 👥 With Acute Myocardial Infarction #PARADISE-MI Trial 👥 STEMI 76%, non–STEMI 24% 👥89% undergone coronary reperfusion ⏰22m 👉SV vs ramipril, ⤵️16% risk of coronary outcomes Asociación CI y Cuidados Agudos Cardiovasculares

Effects of ARNI on Major Coronary Events in 👥 With Acute Myocardial Infarction #PARADISE-MI Trial
👥 STEMI 76%, non–STEMI 24%
👥89% undergone coronary reperfusion
⏰22m
👉SV vs ramipril, ⤵️16% risk of coronary outcomes <a href="/AgudosSEC/">Asociación CI y Cuidados Agudos Cardiovasculares</a>